Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Liver Diseases

  Free Subscription


26.02.2024

1 Am J Gastroenterol
2 Biochem Biophys Res Commun
5 BMC Cancer
1 Cancer Res
1 Dig Dis Sci
1 Endoscopy
3 Eur Radiol
1 Gastrointest Endosc
2 Gut
18 Hepatology
1 Int J Cancer
2 J Gastroenterol Hepatol
15 J Hepatol
1 J Pediatr
1 N Engl J Med
1 Oncogene
1 PLoS One
1 Radiol Artif Intell
2 Radiologia (Engl Ed)
2 Radiology
2 Transplant Proc
3 Transplantation


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Gastroenterol

  1. SASAKI S, Schmidt S, Uldry E, Halkic N, et al
    Hepaticocholecystic Duct: Not a Myth but a Pitfall in Cholecystectomy.
    Am J Gastroenterol. 2024 Feb 19. doi: 10.14309/ajg.0000000000002725.
    PubMed        


    Biochem Biophys Res Commun

  2. KALISHWARALAL K, Azeez Nazeer A, Induja DK, Keerthana CK, et al
    Enhanced extracellular vesicles mediated uttroside B (Utt-B) delivery to Hepatocellular carcinoma cell: Pharmacokinetics based on PBPK modelling.
    Biochem Biophys Res Commun. 2024;703:149648.
    PubMed         Abstract available

  3. CHO W, Oh H, Abd El-Aty AM, Ozten O, et al
    Interleukin-27 as a novel player in alleviating hepatic steatosis: Mechanistic insights from an in vitro analysis.
    Biochem Biophys Res Commun. 2024;703:149671.
    PubMed         Abstract available


    BMC Cancer

  4. ZHANG N, Zhang H, Yang X, Xue Q, et al
    USP14 exhibits high expression levels in hepatocellular carcinoma and plays a crucial role in promoting the growth of liver cancer cells through the HK2/AKT/P62 axis.
    BMC Cancer. 2024;24:237.
    PubMed         Abstract available

  5. YUAN LX, Luo M, Liu RY, Wang HX, et al
    Hsa_circ_0005397 promotes hepatocellular carcinoma progression through EIF4A3.
    BMC Cancer. 2024;24:239.
    PubMed         Abstract available

  6. ZHANG L, Sun T, Sun B, Zhang K, et al
    Utility and predictive value of the CRAFITY score in advanced hepatocellular carcinoma treated with transarterial chemoembolization plus tyrosine kinase inhibitors and PD-1 inhibitor.
    BMC Cancer. 2024;24:223.
    PubMed         Abstract available

  7. WANG K, Cui H, Zhu Y, Hu X, et al
    Evaluation of an artificial intelligence-based clinical trial matching system in Chinese patients with hepatocellular carcinoma: a retrospective study.
    BMC Cancer. 2024;24:246.
    PubMed         Abstract available

  8. YUAN C, Zou S, Wang K, Hu Z, et al
    Establishment and external validation of prognosis prediction nomogram for patients with distant metastatic intrahepatic cholangiocarcinoma: based on a large population.
    BMC Cancer. 2024;24:227.
    PubMed         Abstract available


    Cancer Res

  9. SONG M, Zhang C, Cheng S, Ouyang D, et al
    DNA of neutrophil extracellular traps binds TMCO6 to impair CD8+ T-cell immunity in hepatocellular carcinoma.
    Cancer Res. 2024 Feb 21. doi: 10.1158/0008-5472.CAN-23-2986.
    PubMed         Abstract available


    Dig Dis Sci

  10. ZHAO X, Guo X, Zhao Y, Yu Y, et al
    Gastrointestinal Bleeding Was Diagnosed as Small Intestinal Metastasis of Hepatocellular Carcinoma by Double-Balloon Enteroscopy.
    Dig Dis Sci. 2024 Feb 21. doi: 10.1007/s10620-024-08339.
    PubMed        


    Endoscopy

  11. AMATA M, Boncori G, Scimeca D, Mocciaro F, et al
    Hepatic fascioliasis: a rare case of "fake" biliary gallstones.
    Endoscopy. 2024;56.
    PubMed        


    Eur Radiol

  12. ZHANG A, Meng X, Yao Y, Zhou X, et al
    Head to head comparison of (68)Ga-DOTA-FAPI-04 vs (18)F-FDG PET/CT in the evaluation of primary extrapulmonary tumors in the chest.
    Eur Radiol. 2024;34:1960-1970.
    PubMed         Abstract available

  13. YOO J, Joo I, Jeon SK, Park J, et al
    Utilizing fully-automated 3D organ segmentation for hepatic steatosis assessment with CT attenuation-based parameters.
    Eur Radiol. 2024 Feb 23. doi: 10.1007/s00330-024-10660.
    PubMed         Abstract available

  14. CANNELLA R, Zins M, Brancatelli G
    ESR Essentials: diagnosis of hepatocellular carcinoma-practice recommendations by ESGAR.
    Eur Radiol. 2024 Feb 21. doi: 10.1007/s00330-024-10606.
    PubMed         Abstract available


    Gastrointest Endosc

  15. ISHIWATARI H, Ogura T, Hijioka S, Iwashita T, et al
    Endoscopic ultrasound-guided hepaticogastrostomy versus hepaticogastrostomy with antegrade stenting in patients with unresectable malignant distal biliary obstruction: a propensity score-matched case-control study.
    Gastrointest Endosc. 2024 Feb 19:S0016-5107(24)00109.
    PubMed         Abstract available


    Gut

  16. EL-SERAG H, Kanwal F, Ning J, Powell H, et al
    Serum biomarker signature is predictive of the risk of hepatocellular cancer in patients with cirrhosis.
    Gut. 2024 Feb 16:gutjnl-2024-332034. doi: 10.1136/gutjnl-2024-332034.
    PubMed         Abstract available

  17. LI R, Liu X, Huang X, Zhang D, et al
    Single-cell transcriptomic analysis deciphers heterogenous cancer stem-like cells in colorectal cancer and their organ-specific metastasis.
    Gut. 2023 Nov 30:gutjnl-2023-330243. doi: 10.1136/gutjnl-2023-330243.
    PubMed         Abstract available


    Hepatology

  18. CALTHORPE L, Chiou SH, Rubin J, Huang CY, et al
    A modified hospital frailty risk score for patients with cirrhosis undergoing abdominal operations.
    Hepatology. 2024 Feb 19. doi: 10.1097/HEP.0000000000000794.
    PubMed         Abstract available

  19. PREMKUMAR M, Kajal K, Izzy M, Sihag BK, et al
    Reply to 'liver, heart, and kidney crosstalk in cirrhosis: POCUS is the focus".
    Hepatology. 2024 Feb 16. doi: 10.1097/HEP.0000000000000792.
    PubMed        

  20. PAPATHERODORIDIS G, Lampertico P
    Hepatocellular carcinoma risk in HBeAg-positive chronic hepatitis B patients under long-term nucleos(t)ide analogue therapy: New insights from Asia.
    Hepatology. 2024 Feb 16. doi: 10.1097/HEP.0000000000000796.
    PubMed        

  21. HE B, Huang Z, Qin S, Peng P, et al
    Enhanced SLC35B2/SAV1 sulfation axis promotes tumor growth through inhibiting Hippo signaling in hepatocellular carcinoma.
    Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000783.
    PubMed         Abstract available

  22. PENG Z, Wei G, Huang P, Matta H, et al
    ASK1/p38 axis inhibition blocks the release of mitochondrial "danger signals" from hepatocytes and suppresses progression to cirrhosis and liver cancer.
    Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000801.
    PubMed         Abstract available

  23. ENGELSKIRCHER SA, Chen PC, Strunz B, Oltmanns C, et al
    Impending hepatocellular carcinoma diagnosis in cirrhotic patients after HCV cure features a natural killer cell signature.
    Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000804.
    PubMed         Abstract available

  24. HASSAN MM, Li D, Han Y, Byun J, et al
    Genome-wide association study identifies high-impact susceptibility loci for hepatocellular carcinoma in North America.
    Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000800.
    PubMed         Abstract available

  25. WONG YJ, Teng M, Sim A, Thet HM, et al
    Full adherence to cirrhosis quality indicators is associated with lower mortality in acute variceal bleeding: Nationwide audit.
    Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000793.
    PubMed         Abstract available

  26. LEVY C, Dickey AK, Wang B, Thapar M, et al
    Evidence-based consensus guidelines for the diagnosis and management of protoporphyria-related liver dysfunction in erythropoietic protoporphyria and X-linked protoporphyria.
    Hepatology. 2024;79:731-743.
    PubMed        

  27. LEDENKO M, Antwi SO, Patel T
    Geospatial analysis of cyanobacterial exposure and liver cancer in the contiguous United States.
    Hepatology. 2024;79:575-588.
    PubMed         Abstract available

  28. BARTEN TRM, Atsma F, van der Meer AJ, Gansevoort R, et al
    Higher need for polycystic liver disease therapy in female patients: Sex-specific association between liver volume and need for therapy.
    Hepatology. 2024;79:551-559.
    PubMed         Abstract available

  29. LEE BP, Dodge JL, Terrault NA
    National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature.
    Hepatology. 2024;79:666-673.
    PubMed         Abstract available

  30. WANG F, Chen L, Kong D, Zhang X, et al
    Canonical Wnt signaling promotes HSC glycolysis and liver fibrosis through an LDH-A/HIF-1alpha transcriptional complex.
    Hepatology. 2024;79:606-623.
    PubMed         Abstract available

  31. NICOARA-FARCAU O, Han G, Rudler M, Angrisani D, et al
    Pre-emptive TIPS in high-risk acute variceal bleeding. An updated and revised individual patient data meta-analysis.
    Hepatology. 2024;79:624-635.
    PubMed         Abstract available

  32. LEVY C, Dickey AK, Anderson KE, Keel SB, et al
    Reply: Contrasting effect of iron supplementation in protoporphyria.
    Hepatology. 2024;79:E89-E90.
    PubMed        

  33. BARMAN-AKSOZEN J, Minder AE, Schuppan D, Stolzel U, et al
    Letter to the Editor: Contrasting effect of iron supplementation in protoporphyria.
    Hepatology. 2024;79:E87-E88.
    PubMed        

  34. LAZARUS JV, Newsome PN, Francque SM, Kanwal F, et al
    Reply: A multi-society Delphi consensus statement on new fatty liver disease nomenclature.
    Hepatology. 2024;79:E93-E94.
    PubMed        

  35. HOOFNAGLE JH, Doo E
    Letter to the Editor: A multi-society Delphi consensus statement on new fatty liver disease nomenclature.
    Hepatology. 2024;79:E91-E92.
    PubMed        


    Int J Cancer

  36. QIN XY, Shirakami Y, Honda M, Yeh SH, et al
    Serum MYCN as a predictive biomarker of prognosis and therapeutic response in the prevention of hepatocellular carcinoma recurrence.
    Int J Cancer. 2024 Feb 21. doi: 10.1002/ijc.34893.
    PubMed         Abstract available


    J Gastroenterol Hepatol

  37. WANG J, Zhang Y, Ma Y, Zhao S, et al
    TET1 inhibits liver fibrosis by blocking hepatic stellate cell activation.
    J Gastroenterol Hepatol. 2024 Feb 18. doi: 10.1111/jgh.16443.
    PubMed         Abstract available

  38. BATT NM, Rodrigues B, Bloom S, Sawhney R, et al
    Metabolic-associated fatty liver disease and hepatocellular carcinoma: a prospective study of characteristics and response to therapy.
    J Gastroenterol Hepatol. 2024 Feb 18. doi: 10.1111/jgh.16501.
    PubMed         Abstract available


    J Hepatol

  39. BOESCH M, Lindhorst A, Feio-Azevedo R, Brescia P, et al
    Adipose tissue macrophage dysfunction is associated with a breach of vascular integrity in NASH.
    J Hepatol. 2024;80:397-408.
    PubMed         Abstract available

  40. BENDIXEN SM, Jakobsgaard PR, Hansen D, Hejn KH, et al
    Single cell-resolved study of advanced murine MASH reveals a homeostatic pericyte signaling module.
    J Hepatol. 2024;80:467-481.
    PubMed         Abstract available

  41. IRUZUBIETA P, Santos-Laso A, Arias-Loste MT, Calleja JL, et al
    Evaluation of metabolic dysfunction-associated steatotic liver disease (MASLD) terminology in different clinical settings.
    J Hepatol. 2024;80:e121-e123.
    PubMed        

  42. LEE E, Korf H, Vidal-Puig A
    Reply to: "Liver-adipose tissue crosstalk in nonalcoholic fatty liver disease: the emerging role of remnant cholesterol": "BAT activation might improve NAFLD in patients, but this might require developing and/or maintaining functionally relevant level
    J Hepatol. 2024;80:e112-e114.
    PubMed        

  43. LARRUE H, Bureau C, D'Amico G
    Reply to: "Comment on 'TIPS prevents further decompensation and improves survival in patients with cirrhosis and portal hypertension in an individual patient data meta-analysis'": Further decompensation should now be used as a clinically relevant outc
    J Hepatol. 2024;80:e109-e110.
    PubMed        

  44. LIU Y, Chen M
    Liver-adipose tissue crosstalk in non-alcoholic fatty liver disease: The emerging role of remnant cholesterol.
    J Hepatol. 2024;80:e111-e112.
    PubMed        

  45. BLASZKIEWICZ J, Duncan SA
    Use of stem cell-derived hepatocytes to model liver disease.
    J Hepatol. 2024 Feb 15:S0168-8278(23)05306-0. doi: 10.1016/j.jhep.2023.
    PubMed        

  46. CAON E, Martins M, Hodgetts H, Blanken L, et al
    Exploring the impact of the PNPLA3 I148M variant on primary human hepatic stellate cells using 3D extracellular matrix models.
    J Hepatol. 2024 Feb 14:S0168-8278(24)00110-7. doi: 10.1016/j.jhep.2024.
    PubMed         Abstract available

  47. NARDELLI S, Riggio O, Marra F, Gioia S, et al
    Response to "Hepatic encephalopathy and survival after transjugular intra-hepatic portosystemic shunt: do spontaneous portosystemic shunts matter?".
    J Hepatol. 2024 Feb 14:S0168-8278(24)00122-3. doi: 10.1016/j.jhep.2024.
    PubMed        

  48. YOUNOSSI ZM, Alqahtani SA, Alswat K, Yilmaz Y, et al
    Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease.
    J Hepatol. 2024;80:419-430.
    PubMed         Abstract available

  49. GE X, Desert R, Magdaleno F, Han H, et al
    Redox-sensitive high-mobility group box-1 isoforms contribute to liver fibrosis progression and resolution in mice.
    J Hepatol. 2024;80:482-494.
    PubMed         Abstract available

  50. DIAZ LA, Fuentes-Lopez E, Idalsoaga F, Ayares G, et al
    Association between public health policies on alcohol and worldwide cancer, liver disease and cardiovascular disease outcomes.
    J Hepatol. 2024;80:409-418.
    PubMed         Abstract available

  51. GAMBELLA A, Salvi M, Molinaro L, Patrono D, et al
    Improved assessment of donor liver steatosis using Banff consensus recommendations and deep learning algorithms.
    J Hepatol. 2024;80:495-504.
    PubMed         Abstract available

  52. RUSSO FP, Francque SM, Shawcross DL, Krag AA, et al
    Advocating for the implementation of the new nomenclature for steatotic liver disease: A call to action for the national associations.
    J Hepatol. 2024;80:384-386.
    PubMed        

  53. HAXHE S, Baldin P, Trefois P, Havelange V, et al
    Jaundice with severe leucocytosis.
    J Hepatol. 2024;80:e103-e105.
    PubMed        


    J Pediatr

  54. ZIOGAS IA, Roach JP, Acker SN, Corkum KS, et al
    Association of Sociodemographic Factors with Surgical Management of Hepatoblastoma and Hepatocellular Carcinoma in Children.
    J Pediatr. 2024 Feb 16:113963. doi: 10.1016/j.jpeds.2024.113963.
    PubMed         Abstract available


    N Engl J Med

  55. KOWDLEY KV, Bowlus CL, Levy C, Akarca US, et al
    Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.
    N Engl J Med. 2023 Nov 13. doi: 10.1056/NEJMoa2306185.
    PubMed         Abstract available


    Oncogene

  56. LI B, Xiong X, Xu J, Peng D, et al
    METTL3-mediated m(6)A modification of lncRNA TSPAN12 promotes metastasis of hepatocellular carcinoma through SENP1-depentent deSUMOylation of EIF3I.
    Oncogene. 2024 Feb 19. doi: 10.1038/s41388-024-02970.
    PubMed         Abstract available


    PLoS One

  57. NAIRZ J, Messner A, Kiechl SJ, Winder B, et al
    Determinants of non-alcoholic fatty liver disease in young people: Maternal, neonatal, and adolescent factors.
    PLoS One. 2024;19:e0298800.
    PubMed         Abstract available


    Radiol Artif Intell

  58. PRIOR O, Macarro C, Navarro V, Monreal C, et al
    Identification of Precise 3D CT Radiomics for Habitat Computation by Machine Learning in Cancer.
    Radiol Artif Intell. 2024 Jan 31:e230118. doi: 10.1148/ryai.230118.
    PubMed         Abstract available


    Radiologia (Engl Ed)

  59. REDDY BURSAPALLE M, Valakkadaa J, Ayappan A
    Role of intravoxel incoherent motion (IVIM) imaging in response assessment of hepatocellular carcinoma after transarterial chemoembolization (TACE) - A prospective study.
    Radiologia (Engl Ed). 2024;66:23-31.
    PubMed         Abstract available

  60. ALONSO-GONZALEZ R, Abadal Villayandre JM, Galvez Gonzalez E, Alvarez Perez MJ, et al
    Irreversible electroporation: Beyond the limits of tumor ablation.
    Radiologia (Engl Ed). 2024;66:47-56.
    PubMed         Abstract available


    Radiology

  61. CRIVELLARO P
    A Deeper Look into Ancillary Features in LI-RADS Classification.
    Radiology. 2024;310:e240251.
    PubMed        

  62. DAWIT H, Lam E, McInnes MDF, van der Pol CB, et al
    LI-RADS CT and MRI Ancillary Feature Association with Hepatocellular Carcinoma and Malignancy: An Individual Participant Data Meta-Analysis.
    Radiology. 2024;310:e231501.
    PubMed         Abstract available


    Transplant Proc

  63. KIM SM, Yoon YI, Moon DB, Kim KH, et al
    Achieving 400 Living Donor Liver Transplantations Annually During the COVID-19 Pandemic: A Single-Center Experience.
    Transplant Proc. 2024 Jan 31:S0041-1345(23)00788.
    PubMed         Abstract available

  64. ISHII M, Hirukawa K, Shimata K, Yoshimaru Y, et al
    The First Successful Living Donor Liver Transplantation for Acute-on-Chronic Liver Failure Caused by Severe Acute Necrotizing Pancreatitis: A Case Report.
    Transplant Proc. 2024 Jan 12:S0041-1345(23)00775.
    PubMed         Abstract available


    Transplantation

  65. SEDKI M, Kwong A, Bhargava M, Ahmed A, et al
    Alcohol Use in Liver Transplant Recipients With Alcohol-related Liver Disease: A Comparative Assessment of Relapse Prediction Models.
    Transplantation. 2023 Oct 30. doi: 10.1097/TP.0000000000004800.
    PubMed         Abstract available

  66. ROSENTHAL BE, Abt PL, Schaubel DE, Reddy KR, et al
    Living Donor Liver Transplantation for Adults With High Model for End-stage Liver Disease Score: The US Experience.
    Transplantation. 2023 Aug 28. doi: 10.1097/TP.0000000000004767.
    PubMed         Abstract available

  67. BRANAGAN WT, Norvell JP
    Assessment and Evaluation of Alcohol Use Disorder in Liver Transplant.
    Transplantation. 2023 Jul 6. doi: 10.1097/TP.0000000000004722.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.